


575 F.3d 1341
United States Court of Appeals,
Federal Circuit.
BAYER SCHERING PHARMA AG and Bayer Healthcare Pharmaceuticals, Inc., Plaintiffs-Appellants,
v.
BARR LABORATORIES, INC., Defendant-Appellee.
No. 2008-1282.
|
Aug. 5, 2009.
|
Rehearing and Rehearing En Banc Denied Oct. 26, 2009.
Synopsis
Background: Patent owner filed action against competitor alleging infringement. The United States District Court for the District of New Jersey, Peter G. Sheridan, J., 2008 WL 628592, concluded that patent was invalid due to obviousness. Owner appealed.
 
The Court of Appeals, Mayer, Circuit Judge, held that innovation to micronize drospirenone to increase its bioavailability, and that micronized drospirenone would absorb with normal pill, was obvious.
 
Affirmed.
 
Newman, Circuit Judge, filed dissenting opinion.
 
